Integrins as a drug target in liver fibrosis. (28th January 2022)

• Record Type: Journal Article
• Authors: Rahman, Syedia R.; Roper, James A.; Grove, Jane I.; Aithal, Guruprasad P.; Pun, K. Tao; Bennett, Andrew J.
• Is Part Of: Liver international. Volume 42:Number 3(2022)
• Page Start: 507
• Page End: 521
• Publication Date: 2022-01-28
• Subjects: fibrosis -- integrins -- liver cirrhosis -- liver disease -- non‐alcoholic steatohepatitis; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.15157
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: As the worldwide prevalence of chronic liver diseases is high and continuing to increase, there is an urgent need for treatment to prevent cirrhosis‐related morbidity and mortality. Integrins are heterodimeric cell‐surface proteins that are promising targets for therapeutic intervention. αv integrins are central in the development of fibrosis as they activate latent TGFβ, a known profibrogenic cytokine. The αv subunit can form heterodimers with β1, β3, β5, β6 or β8 subunits and one or more of these integrins are central to the development of liver fibrosis, however, their relative importance is not understood. This review summarises the current knowledge of αv integrins and their respective β subunits in different organs, with a focus on liver fibrosis and the emerging preclinical and clinical data with regards to αv integrin inhibitors.